Skip to main content

Advertisement

Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro

Fig. 3

Baricitinib reverses behavioral abnormalities conferred by HIV in vivo. Discrimination index for novel object testing on days 5 and 6 (5 min delay or 2 h delay, a and b respectively) demonstrates that HAND (HIV) mice (untreated) cannot discriminate novel versus familiar object. However, uninfected control mice can discriminate. Day 12 and 13 ORT data demonstrate that uninfected mice can discriminate between novel and familiar objects; HIV infection significantly reduces ability of mice to discriminate between novel and familiar objects (c, d). Ten milligrams per kilogram and 50 mg/kg baricitinib restore the ability to discriminate to the level of the control mice (c, d). *p < 0.01, **p < 0.001. HAND (HIV) mice were compared to sham controls, and treated groups were compared to HAND (HIV) group

Back to article page